Brain+ A/S
Quotes
Share:
Subscribe:
news.cision.com
/
Brain+ A/S
/
Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST
/
1 B EN RGB
1 B EN RGB
Fri, Jun 24, 2022 08:30 CET
new
Low resolution
Medium resolution
Original resolution
Subscribe
Related Releases
Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue
Mon, Oct 07, 2024 11:50 CET
Brain+ launches Ayla – your CST Assistant into the UK dementia market
Wed, Oct 02, 2024 10:32 CET
Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions
Tue, Oct 01, 2024 12:11 CET
